Study Identifies Causes of Death in Myeloproliferative Neoplasms

Share this content:

the Cancer Therapy Advisor take:

Patients with myeloproliferative neoplasms (MPNs) have a higher mortality rate compared to matched controls due to hematologic malignancy, infections and vascular events in younger patients, according to a Swedish population study published online ahead of print in the Journal of Clinical Oncology.

Researchers led by Malin Hultcrantz, MD, PhD, of the Karolinska University Hospital in Stockholm identified 9,285 patients with MPN from Swedish registries in order to assess cause of death in these patients when matched with controls.

They found that risk of death from cardiovascular and cerebrovascular disease in patients aged 70 to 79 were statistically significantly elevated compared to matched controls. In patients aged 50 to 59 at time of diagnosis, the ten-year probability of death from cardiovascular or cerebrovascular disease was higher.

They also found that survival in patients with MPN increased over time due to decreased probabilities of dying as a result of hematologic malignancies, infections and cardiovascular disease in younger patients.

“There is still a need for effective disease-modifying agents to improve patient outcomes,” the authors concluded.

Cancer of Unknown Origin: A Diagnostic and Treatment Dilemma
Patients with MPNs have a higher mortality rate due to hematologic malignancy and vascular events.
Myeloproliferative neoplasms (MPNs) are associated with a shortened life expectancy. We assessed causes of death in patients with MPN and matched controls using both relative risks and absolute probabilities in the presence of competing risks.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs